Angiogenesis in hematology: A field of active research

Leukemia Research

Volumn 27, Issue 7, 2003, Pages 571-573

  Raimondo, Francesco Di ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR; NEUROPILIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANGIOGENESIS; AUTOCRINE EFFECT; BLOOD ANALYSIS; BONE MARROW; CANCER CELL; CANCER PATIENT; CANCER SURVIVAL; CELL LINEAGE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL STIMULATION; CHEMOTAXIS; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CORRELATION ANALYSIS; DENSITY; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HEALTH STATUS; HEMATOLOGY; HEMATOPOIESIS; HUMAN; KNOCKOUT MOUSE; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MACROPHAGE; MICROVASCULATURE; MONOCYTE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SOLID TUMOR; STEM CELL; TARGET CELL; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 0037411294     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00328-4     Document Type: Editorial

References (42)

1. Weidner N, Folkman J. Tumor vascularity as a prognostic factor in cancer. In: De Vita V, Helmann S, Rosenberg SA, editors. Important advances in oncology. Lippincott-Raven; 1996. p. 167-90.
2. Mangi M.H., Newland A.C. Angiogenesis and angiogenic mediators in haematological malignancies. Br. J. Haematol. 111:2000;43-51.
3. Giustolisi R., Di Raimondo F. Angiogenesis in hematology. Acta Haematol. 4:2001;147-220.
4. Perez-Atayde A.R., Sallan S.E., Tedrow U., Connors S., Allred E., Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150:1997;815-821.
5. Vacca A., Ribatti D., Presta M., Monischetti M., Iurlaro M., Ria R.et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 93:1999;3064-3073.
6. Ribatti D., Vacca A., Nico B., Fanelli M., Roncali L., Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur. J. Haematol. 56:1996;45-53.
7. Pruneri G., Bertolini F., Soligo D., Carboni N., Cortelezzi A., Ferrucci P.F.et al. Angiogenesis in myelodysplastic syndromes. Br. J. Cancer. 81:1999;1398-1401.
8. Korkolopoulou P., Apostolidou E., Pavlopoulos P.M., Kavantzas N., Vyniou N., Thymara I.et al. Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia. 15:2001;1369-1376.
9. Hussong J.W., Rodgers G.M., Shami P.J. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 95:2000;309-313.
10. Padrò T., Ruiz S., Bieker R., Burger H., Steins M., Kienast J.et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 95:2000;2637-2644.
11. Molica S., Vacca A., Ribatti D., Cuneo A., Cavazzini F., Levato D.et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 100:2002;3344-3351.
12. Lundberg L.G., Lerner R., Sundelin P., Rogers R., Folkman J., Palmblad J. Bone marrow in polycytemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am. J. Pathol. 157:2000;15-19.
13. Vermeulen P.B., Gasparini G., Fox S.B., Toi M., Martin L., McCulloch P.et al. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer. 32A:1996;2474-2484.
14. Tung-Ping Poon R., Fan S.T., Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 19:2001;1207-1225.
15. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
16. Ferrara N., Davis-Smyth T. Biology of vascular endothelial growth factor. Endocrinol. Rev. 18:1997;4-25.
17. Dvorak H. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:2002;4368-4380.
18. Kim J. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vitro. Nature. 362:1993;841-844.
19. Bussolino F., Di Renzo M.F., Ziche M., Bocchietto E., Olivero M., Naldini L.et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 119:1992;629-641.
20. Aguayo A., Kantarjian H., Manshouri T., Gidel C., Estey E.et al. Agiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 96:2000;2240-2245.
21. Di Raimondo F., Azzaro M.P., Palumbo G.A., Bagnato S., Giustolisi G., Floridia P.M.et al. Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica. 85:2000;800-805.
22. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin. Chem. 47:2001;617-623.
23. Di Raimondo F., Azzaro M.P., Palumbo G.A., Bagnato S., Stagno F., Giustolisi G.et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia. 15:2001;976-980.
24. Molica S., Vitelli G., Levato D., Gandolfo G.M., Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leucemia. Br. J. Haematol. 107:1999;605-610.
25. Salven P., Orpana A., Teerhenovi L., Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factor VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood. 96:2000;3712-3718.
26. Borset M., Hjort-hansen H., Seidel C., Sundan A., Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood. 88:1996;3998-4004.
27. Verstovsek S., Kantarjian H., Estey E., Aguayo A., Giles F.J., Manshouri T.et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 15:2001;1165-1170.
28. Gille H., Kowalski J., Li B., LeCouter J., Moffat B.et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276:2001;3222-3230.
29. Veikkola T., Karkkainen M., Claesson-Welsh L., Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60:2000;203-212.
30. Shalaby F., Ho J., Stanford W.L., Fischer K.D., Schuh A.C., Schwartz L.et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 89:1997;981-990.
31. Pelosi E., Valtieri M., Coppola S., Botta R., Gabbianelli M., Lulli V.et al. Identification of the hemangioblast in postnatal life. Blood. 100:2002;3203-3208.
32. Zeng H., Dvorak H.F., Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J. Biol. Chem. 276:2001;26969-26979.
33. Bernatchez P.N., Rollin S., Soker S., Sirois M.G. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: role of neuropilin-1. J. Cell Biochem. 85:2002;629-639.
34. Bellamy W.T., Richter L., Frutiger Y., Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 59:1999;728-733.
35. Pons E., Uphoff C.C., Drexler H.G. Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines. Leuk. Res. 22:1998;797-804.
36. Fiedler W., Graeven U., Ergun S., Verago S., Kilic N., Stockschlader M.et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 89:1997;1870-1875.
37. Dias S., Hattori K., Zhu Z., Heissig B., Choy M., Lane W.et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 106:2000;511-521.
38. Dias S., Choy M., Alitalo K., Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 99:2002;2179-2184.
39. Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, et al. Clinical relevance of VEGF receptor 1 and 2 in patients with chronic myelogenous leukemia, Leuk Res 27.
40. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 87:1996;3336-3343.
41. Dias S, Lane WJ, Wu Y, Choy M, Peichev M, Chadburn A, et al. Neutralizing MoAb to VEGF receptors inhibit proliferation and migration of a subset of human leukemias through interaction with VEGFR-2(KDR) and VEGFR-1(FLT-1). In: Proceedings of the 41st Meeting of the Am. Soc. Hemat. Blood 1999;94(Suppl 1):2754.
42. Dias S., Hattori K., Heissig B., Zhu Z., Wu W., Witte L.et al. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. PNAS. 98:2001;10857-10862.